Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pargluva Rejection Urged By Public Citizen

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee's recommendation for approval of Bristol-Myers Squibb's diabetes agent was "inappropriate" because it was based on "vague promises" from industry, Public Citizen says in a letter to the agency.

You may also be interested in...

Pargluva Development May Be Terminated By Bristol, Merck

Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.

Bristol/Merck's Pargluva Combination Use With Sulfonylureas Not Recommended

Committee supports use of the type 2 diabetes therapy muraglitazar as monotherapy and in combination with metformin, but says safety with sulfonylureas has not been adequately studied.

A Whole New Year For Pharma: Macro Pressures Mount Heading Into Q1 Reporting

First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts